# Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

> **NCT04676893** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 56 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** D418 Tab.
- **DRUG:** CKD-388 Tab.

## Key facts

- **NCT ID:** NCT04676893
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-26
- **Primary completion:** 2021-05-11
- **Final completion:** 2021-05-18
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676893, "Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*